DEA Finalizes Schedule III Case in August, Marking Key Rescheduling Milestone

DEA closed the administrative case file on Schedule III rescheduling in August 2026.

According to Cannabis Business Times, finalization of DEA's Schedule III case was the top cannabis industry story in August. The agency's completion of the administrative record means all public comments, expert testimony, and agency responses have been compiled and reviewed. Under the Administrative Procedure Act, DEA must now issue a final rule or withdraw the proposed rescheduling.

The agency hasn't announced a publication date for the final rule. Industry observers expect action before year-end 2026, though DEA retains discretion over timing.

HHS recommended Schedule III placement in August 2023, triggering DEA rulemaking.

The Department of Health and Human Services submitted its scientific and medical evaluation to DEA on August 29, 2023, concluding that cannabis meets the statutory criteria for Schedule III under the Controlled Substances Act. DEA published a Notice of Proposed Rulemaking in May 2024, opening a 60-day comment period that drew more than 43,000 submissions.

Administrative law judge hearings followed in December 2024 and February 2025. The agency took testimony from medical researchers, state regulators, and industry stakeholders. For full background on this story, see the CannIntel topic hub on DEA Schedule III rescheduling.

Rescheduling to Schedule III would end IRC §280E prohibitions on most business deductions.

Under Internal Revenue Code §280E, businesses trafficking in Schedule I or Schedule II controlled substances can't deduct ordinary business expenses. If cannabis moves to Schedule III, the statute no longer applies. Operators could deduct payroll, rent, marketing, and other expenses on federal tax returns.

Cost of goods sold deductions—currently the only allowable write-off for cannabis retailers—would remain available. The net effect? Effective tax rates would drop from an estimated 70% to rates comparable to other industries, typically 25-35% depending on state tax treatment.

State-licensed operators remain subject to federal prosecution under Schedule III.

Schedule III substances are federally legal only with a valid DEA registration and prescription. Cannabis dispensaries operating under state licenses don't meet this standard. Read the Controlled Substances Act strictly, and state-legal sales remain federal trafficking offenses even after rescheduling.

DOJ enforcement priorities historically focus on diversion, interstate trafficking, and organized crime. The Cole Memo framework—rescinded in 2018 but informally observed—suggests federal prosecutors would continue to defer to state-compliant operators. No formal prosecutorial guidance has been issued for a Schedule III cannabis regime.

Banking access and capital markets remain constrained without additional legislative action.

The Bank Secrecy Act and anti-money-laundering regulations apply to proceeds from any federal controlled substance offense. Schedule III rescheduling doesn't remove cannabis from the Controlled Substances Act. Banks filing Suspicious Activity Reports under FinCEN guidance would still classify cannabis deposits as proceeds of federal crimes.

The SAFE Banking Act passed the House seven times between 2019 and 2024. It would provide explicit safe harbor for financial institutions serving state-licensed cannabis businesses, but the bill hasn't advanced in the Senate. Nasdaq and NYSE listing rules prohibit companies engaged in federally illegal activity; those rules would require amendment to permit cannabis MSO listings under Schedule III.

International treaty obligations under the 1961 Single Convention may complicate implementation.

The United States is a signatory to the 1961 Single Convention on Narcotic Drugs, which classifies cannabis as a Schedule I substance requiring the strictest controls. Domestic rescheduling to Schedule III doesn't alter treaty obligations. The U.S. could invoke the treaty's reservation process or seek amendment through the United Nations Commission on Narcotic Drugs.

Canada and Uruguay, both Single Convention signatories, have implemented adult-use legalization regimes while remaining in technical non-compliance with treaty text. The U.S. State Department hasn't issued formal guidance on how Schedule III rescheduling would be reconciled with treaty obligations.

Next step: publication of a final rule in the Federal Register, expected before December 31, 2026.

DEA will publish either a final rule adopting Schedule III rescheduling, a final rule declining to reschedule, or a supplemental notice reopening the comment period. The Administrative Procedure Act doesn't impose a deadline, but the agency's completion of the administrative record in August signals imminent action.

Effective dates for final rules typically range from 30 to 90 days after Federal Register publication, allowing regulated entities time to achieve compliance. We're watching three indicators: Federal Register filings, DOJ guidance on prosecutorial priorities, and IRS interpretation of §280E cessation for Schedule III substances.